Active substanceNaphthyfinNaphthyfin
Similar drugsTo uncover
  • Mizol® Evalar
    solution externally 
    EVALAR, CJSC     Russia
  • Mikoderil®
    cream externally 
    OTISIFARM, OJSC     Russia
  • Mikoderil®
    solution externally 
    OTISIFARM, OJSC     Russia
  • Naphthyfin
    solution externally 
  • Naphthyfin
    cream externally 
  • Exoderyl®
    solution externally 
    Sandoz GmbH     Austria
  • Exoderyl®
    cream externally 
    Sandoz GmbH     Austria
  • Exostat
    solution externally 
    VERTEKS, AO     Russia
  • Exostat
    cream externally 
    VERTEKS, AO     Russia
  • Dosage form: & nbspcream for external use
    Composition:

    1 g of cream contains:

    Active substance: naftifin hydrochloride 10.0 mg.

    Excipients: sodium hydroxide 1.2 mg, benzyl alcohol 10.0 mg, sorbitan stearate 19.0 mg, cetyl palmitate 20.0 mg, polysorbate 60-61.0 mg, cetostearyl alcohol 80.0 mg, isopropyl myristate - 80.0 mg, purified water - up to 1000 mg.

    Description:White homogeneous cream with a weak specific odor.
    Pharmacotherapeutic group:Antifungal agent
    ATX: & nbsp

    D.01.A.E.22   Naphthyfin

    Pharmacodynamics:

    Naphthyfine is an antifungal agent for external use, which belongs to the class of allylamines. The mechanism of action is associated with the inhibition of squalene-2,3-epoxidase, which leads to a decrease in the formation of ergosgerol, which is part of the cell wall of the fungus. It is active against dermatophytes, such as trichophyton, epidermophyton and microsporum, mold (Aspergillus spp.), yeast fungi (Candida spp., Pityrosporum) and other fungi (for example. Sporothrix schenckii). In relation to dermatophytes and aspergillus naphthyline is fungicidal. With regard to yeast fungi, the preparation shows fungicidal or fungistatic activity, depending on the strain of the microorganism. Has antibacterial activity against gram-positive and gram-negative microorganisms that can cause secondary bacterial infections. Has an anti-inflammatory effect, which contributes to the rapid disappearance of symptoms of inflammation, especially itching.

    Pharmacokinetics:

    With external application it penetrates well into various layers of the skin, creating stable antifungal concentrations in its various layers. After applying systemic absorption to the skin, less than 6% of the naphthipipe is exposed. The absorbed amount is partially metabolized and excreted by the kidneys and through the intestine. The period of excretion of the drug is 2-3 days.

    Indications:

    - Fungal infections of smooth skin and skin folds (tinea corporis, tinea inquinalis);

    - interdigital mycoses (tinea manum, tinea pedum);

    - fungal infections of the nails (onychomycosis);

    - candidiasis of the skin;

    - pityriasis lichen;

    - dermatomycosis (with or without itching).

    Contraindications:

    Hypersensitivity to naphthyfine, benzene alcohol or other components of the drug; pregnancy and lactation period (safety and efficacy of the drug in this category of patients has not been studied).

    Carefully:Children's age (clinical experience is limited).
    Pregnancy and lactation:

    The use of the drug during pregnancy and during lactation is contraindicated (the safety and efficacy of the drug in this category of patients has not been studied).

    Dosing and Administration:

    Outwardly.

    When skin is affected Mikoderil® is applied once a day to the affected surface of the skin and adjacent areas, after thorough cleaning and drying (taking about 1 cm of a healthy area of ​​the skin along the edges of the affected area).

    Duration of therapy with dermatomycosis - 2-4 weeks (if necessary - up to 8 weeks), with candidiasis - 4 weeks.

    When the nails are affected Mikoderil® is applied 2 times a day to the affected nail. Before the first use of the drug, remove the affected part of the nail with scissors or a nail file.

    The duration of therapy with onychomycosis is up to 6 months.

    To prevent recurrence, treatment should be continued for at least 2 weeks after the disappearance of clinical symptoms.

    Side effects:

    There may be reactions at the site of application: dry skin, skin hyperemia and burning. Side effects are reversible and do not require withdrawal of treatment. If any of the side effects indicated in the manual are aggravated, or any other side effects not indicated in the instructions are noted, the doctor should be informed immediately.

    Overdose:No cases of overdose have been reported.
    Interaction:Not studied.
    Special instructions:

    Required course treatment.

    Precautions for use:

    Mikoderil® is not intended for use in ophthalmology. Do not allow the product to enter the eyes.

    Use in Pediatrics:

    with caution should be used in children under 18 years of age (efficacy and safety of the drug is not proven).

    Effect on the ability to drive transp. cf. and fur:
    Mycoderil® does not adversely affect the ability to drive vehicles and perform other activities requiring concentration of attention and speed of psychomotor reactions.
    Form release / dosage:

    Cream for external use, 1%.

    Packaging:

    By 10 g, 15 g, 20 g, 25 g, 30 g, 35 g, 40 g, 50 g or 100 g in aluminum tubes.

    Tubu together with instructions for medical use are placed in a pack of cardboard.

    Storage conditions:

    At a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:3 years. Do not use after the expiry date printed on the package.
    Terms of leave from pharmacies:Without recipe
    Registration number:LP-003053
    Date of registration:22.06.2015 / 15.03.2018
    Expiration Date:22.06.2020
    The owner of the registration certificate:OTISIFARM, OJSC OTISIFARM, OJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp23.04.2018
    Illustrated instructions
      Instructions
      Up